{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:26:00Z","timestamp":1787199960253,"version":"build-2736575974"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Compound\n                    <jats:italic>BCR<\/jats:italic>\n                    ::\n                    <jats:italic>ABL1<\/jats:italic>\n                    mutations, particularly those including T315I in combination with P-loop substitutions, represent a major therapeutic challenge in advanced-phase chronic myeloid leukemia (CML). Clinical evidence supporting dual ATP-site and allosteric inhibition in this setting remains limited. We report a heavily pretreated patient with myeloid blast-phase CML in whom next-generation sequencing at blast transformation identified Y253H, T315I, and a low-level Y253_E255delinsHGK variant. Importantly, phasing analysis demonstrated that Y253H and T315I were present on the same\n                    <jats:italic>BCR<\/jats:italic>\n                    ::\n                    <jats:italic>ABL1<\/jats:italic>\n                    allele, confirming a true compound mutation. Given the aggressive disease biology, limited therapeutic options, and transplant intent, the patient received ponatinib 45 mg once daily plus asciminib 200 mg twice daily as an individualized bridge strategy. After 4 weeks of treatment, bone marrow evaluation showed a transient reduction in blast burden. However, treatment exposure was brief and interrupted by pancreatitis, no molecular response was documented, and rapid relapse occurred before planned allogeneic transplantation. This case should therefore not be interpreted as evidence of efficacy. Rather, it provides a cautious, hypothesis-generating clinical observation suggesting possible short-term activity of dual ATP-site and allosteric inhibition in a highly resistant setting. This case also highlights the potential value of long-read sequencing-based mutation profiling with phasing in advanced-phase CML, where distinguishing true compound mutations from separate subclones may be clinically relevant.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1928961","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:16:00Z","timestamp":1787199360000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Ponatinib plus asciminib in myeloid blast-phase CML harboring a phased BCR::ABL1 Y253H\/T315I compound mutation: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Yingying","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Hematology, Hospital of Chengdu Office of the People's Government of Xizang Autonomous Region","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbing","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Hematology, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"He","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital of Chengdu Office of the People's Government of Xizang Autonomous Region","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.beha.2016.10.005","article-title":"Management of CML-blast crisis","volume":"29","author":"Hehlmann","year":"2016","journal-title":"Best Pract Res Clin Haematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002969","article-title":"Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study","volume":"135","author":"Soverini","year":"2020","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b01040","article-title":"Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1","volume":"61","author":"Schoepfer","year":"2018","journal-title":"J Med Chem"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.08.004","article-title":"Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants","volume":"36","author":"Eide","year":"2019","journal-title":"Cancer Cell"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.176347","article-title":"BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib","volume":"103","author":"Byrgazov","year":"2018","journal-title":"Haematologica"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-431379","article-title":"BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships","volume":"121","author":"Khorashad","year":"2013","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-019-0815-5","article-title":"Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper","volume":"12","author":"Soverini","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s12254-021-00742-0","article-title":"Ponatinib and palbociclib combination in TKI-resistant CML\u2014a case report","volume":"14","author":"Jaeger","year":"2021","journal-title":"memo"},{"key":"B14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.leukres.2018.12.013","article-title":"A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1(T315I) in Ph+ CML","volume":"78","author":"Gleixner","year":"2019","journal-title":"Leuk Res"},{"key":"B15","article-title":"Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1(T315I)-compound mutations","volume":"11","author":"Gleixner","year":"2021","journal-title":"Am J Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"E9","DOI":"10.1002\/ajh.27095","article-title":"Combinatorial treatment options for highly resistant compound mutations in the kinase domain of the BCR::ABL1 fusion gene in Ph-positive leukemias","volume":"99","author":"Sponseiler","year":"2024","journal-title":"Am J Hematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.08.004","article-title":"Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy","volume":"42","author":"Eide","year":"2024","journal-title":"Cancer Cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.289085","article-title":"Combined asciminib and olverembatinib in blast-phase chronic myeloid leukemia","volume":"111","author":"Cheng","year":"2025","journal-title":"Haematologica"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1928961\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:16:01Z","timestamp":1787199361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1928961\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":19,"alternative-id":["10.3389\/fonc.2026.1928961"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1928961","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"article-number":"1928961"}}